Do You Have to Quit Drinking Entirely?

Two conversations recur in my practice. Neither describes a particular person; both describe a pattern I see often enough that the details have blurred into a type.

In the first, someone successful is doing the arithmetic on their evenings. Nothing has fallen apart and the work still gets done. But two glasses became four somewhere in the last few years, the sleep is bad, and the private question is whether this is a problem yet and what admitting it would cost. In the second, someone is in my office because a spouse asked them to come. They are not sure they belong here, and they are quite sure they do not want to be told they can never drink again.

Both are asking the same question, and in my experience it keeps people out of treatment longer than almost anything else: do I have to quit entirely?

The honest answer depends on your goals, your severity, and what you are trying to protect. That is not a dodge. Modern addiction medicine has a real framework for this decision, and it is not the framework the public argument implies.

The argument you have already heard

The public conversation offers two camps. One is the abstinence tradition: Alcoholics Anonymous, residential rehab, the idea that you must hit bottom before you can climb. It has helped an enormous number of people, and its core insight is sound, because when drinking has genuinely taken the wheel a clear line is easier to hold than a negotiated one.

The other is harm reduction, which holds that people not ready to stop still deserve care, and that reducing damage is a legitimate medical goal rather than a consolation prize. That insight is also sound, and it corrects something the first tradition gets badly wrong: the assumption that a person must want what we want before we will help them.

The reframe: tools matched to goals

Treated as ideologies, these positions are irreconcilable, and the fight consumes a great deal of energy. They are not ideologies. They are tools, and the question is which one serves the goal in front of you.

One person wants to optimize function and outcome. They have a career, a family, and a long horizon, and they want their brain, liver, and sleep working at capacity for decades. For that person a period of complete abstinence is often the higher-performing choice, not a moral position. Another person is not there and may not get there. For them, drinking less, drinking more safely, and staying connected to medical care is the right medicine, and insisting otherwise mostly means they disappear.

Our practice tends to work with the first goal, because those are the people who seek us out. But we keep the nonjudgmental posture harm reduction pioneered, whatever the goal. You can hold a high standard without attaching shame, and that works better than either half alone.

A word about language. People search for the phrase "high-functioning alcoholic," and I understand why, but I do not use it or its shorter form for my patients. The evidence here is not merely sentimental: when clinicians read case descriptions identical except for whether the person is called a substance abuser or described as having a substance use disorder, they judge the same patient as more blameworthy and more deserving of punishment. If terminology moves trained professionals that much, it is worth getting right.

We do not talk about forever

When someone starts treatment with us, we almost never frame the goal as permanent abstinence. We frame it as a six-month experiment, with a decision point at month five about what the next period should look like.

This is a practice convention with a clinical rationale, not a threshold established by any trial. Severity matters. In general population data, greater severity of alcohol dependence is associated with higher odds of recovering through abstinence and lower odds of recovering while still drinking. In our experience, people who seek out a practice like ours are usually far enough along that moderation attempted from inside active drinking is a poor bet. You also cannot evaluate your capacity to moderate while everything that would inform the judgment is distorted. Insomnia in alcohol use disorder commonly persists well past the first weeks of sobriety and predicts relapse; mood follows a similarly slow curve, and the brain's reward system takes time to move back toward baseline. Ask someone in week three whether they can drink normally, and you are asking a question the data cannot yet answer.

Most importantly, "forever" is the wrong unit. It is an identity claim, it is frightening, and it stops people from starting. Six months is a bounded, reversible experiment a person can actually agree to. At month five we sit down with real information and decide together what comes next: sometimes continued abstinence, sometimes a carefully structured trial of moderation.

I want to be straight about the tension here. Non-abstinent recovery is real and not rare. Following people for years after alcohol treatment, researchers have repeatedly found a substantial group living well while still drinking sometimes: 16.9 percent of the Project MATCH sample at three years, and 19.4 percent in an independent replication using the COMBINE study. Both were treatment-seeking, alcohol-dependent populations, not people with mild problems. So the claim is not that moderation is impossible for someone like you. It is narrower: a decision made from six months of clear data beats one made from hope.

What the medications actually do

Most people are surprised there are medications for this at all. They work about as well as the drugs we prescribe without hesitation for other conditions, and they are dramatically less used.

The approved options come first. Naltrexone and acamprosate are FDA approved and are recommended as first-line treatment alongside psychosocial care. In the pooled outpatient trials, naltrexone helps roughly one in twelve people treated avoid a return to heavy drinking. Acamprosate helps a similar share stay away from drinking altogether, though it has not shown a clear effect specifically on heavy drinking.

That one-in-twelve figure deserves context, because addiction medicine gets graded on a curve nobody applies to the rest of medicine. Statins for primary prevention help on the order of one in a hundred. For aspirin after a heart attack the number is in the dozens. Naltrexone sits in the same range as the drugs we use for smoking cessation, and no one calls those futile. These medications are not miracle cures, and they are also not the weak tea their near-total absence from American practice would suggest. Naltrexone can also be taken before anticipated drinking rather than daily, an off-label use of an approved drug that I discuss as such.

Disulfiram belongs here with a caveat. It does not touch craving and does little on its own, and in the trials the benefit turned up mainly where someone else oversaw the dose. Read carefully, that is less a failed drug than a drug whose mechanism is accountability rather than pharmacology. We use it as an added layer on a treatment structure already doing the main work. Patients sometimes take it independently once that structure is in place, and often for defined higher-risk stretches such as travel, when they want the decision made before they reach the hotel bar. It belongs under medical supervision, because the reaction it produces with alcohol can be severe.

Beyond the approved options, the evidence is mixed or limited, and I will not pretend otherwise. A wider toolbox matters, but these are further options when first-line treatment falls short, not better ones hiding behind a prescription pad.

Baclofen has the most contested record. A 2023 Cochrane review concluded it likely reduces relapse and increases abstinent days, mainly in people who had already completed detoxification, though it probably does not reduce heavy drinking. Systematic reviewers rate the overall evidence as low strength. It also carries a real safety signal: a large French national study found hospitalization and death rising with dose, concentrated at the highest doses, with no excess in deaths at the lowest ones.

My reading, offered as clinical interpretation rather than evidence: baclofen is an abstinence drug, and I do not consider it safe to combine with active drinking. That distinction matters for how we should read the safety data, because France, where most of the concerning data comes from, never required patients to stop drinking before starting it. So the honest position is that we do not know how much of that risk transfers to a population using the drug differently. The study that found the signal recorded nothing at all about how much its patients were drinking, which means it cannot separate the risk of baclofen from the risk of drinking heavily while taking it. I read that as a reason for caution and close supervision rather than a reason to dismiss the finding, and it is why we use baclofen only in patients who have stopped drinking.

In our practice, on that footing, baclofen has been well tolerated and helpful for many people, with rare exceptions such as mania, which I have seen a small number of times. That is experience, not a trial, and the dose matters enormously, which is why this is not a drug to take casually or without close follow-up.

Gabapentin has a randomized trial showing benefit in people with alcohol withdrawal symptoms, strongest in those whose withdrawal symptoms were most pronounced, though the subgroup was small and reviewers rate the overall evidence as low strength. A meta-analysis supports topiramate at small to moderate effect sizes, offset by cognitive and sensory side effects that lead some people to stop.

The newest area is GLP-1 medications, and the honest status is promising, not established. Three randomized trials have tested them in alcohol use disorder. The first missed its primary endpoint entirely. The second, nine weeks in 48 people, did not change how many days people drank. The third enrolled people who had both alcohol use disorder and obesity. Published this year, it found a genuine benefit on heavy drinking when semaglutide was added to therapy that both groups received. You may have seen a 41 percent figure in the press; that is the treated group's change from its own starting point, and the placebo group improved substantially too, so the real difference between them was closer to 14 percentage points. It is not standard of care, and the evidence so far is strongest in people who also carry obesity.

We have no financial relationship with any medication manufacturer, monitoring company, or treatment facility, and no arrangement that pays us for a referral.

The part that is not the prescription

If you read only the drug trials, you would conclude that alcohol treatment is a pharmacy problem. The larger trials say something more interesting.

COMBINE, the biggest American trial of alcohol treatment, randomized 1,383 people across eight combinations of medication and therapy. The result everyone quotes is that naltrexone worked. The result that deserves more attention is what happened to everyone. Percent of days abstinent landed between 75 and 81 percent in every active group, among people who arrived with alcohol dependence. Nothing in that trial failed in absolute terms. What the trial could not find was a winner: medication with structured medical management, specialist behavioral therapy with medical management, and both together all performed about the same. That is not a disappointing result. It means there is more than one road, and that is the entire argument for choosing the road that fits the person rather than running everybody through one protocol.

Buried inside the same trial is the finding I think about most. One group received specialist behavioral therapy with no pills and no physician contact, and it did worse than the group that got placebo pills plus structured meetings with a clinician: about 67 percent days abstinent against about 75. The authors wrote plainly that meeting with a health care professional had a positive effect beyond the therapy itself. Regular, structured contact with a clinician is not the wrapper around the treatment. It is part of the treatment.

Then there is the problem that dwarfs all of this. In national survey data, only about a quarter of people who have been alcohol dependent ever receive any treatment at all. The field's central failure is not weak medicine. It is medicine that never arrives. When researchers built integrated care into primary care clinics, the share of patients who received evidence-based treatment rose from 17 percent to 39 percent. Getting people treated is where the largest and most reliable gains sit, and it is most of what a practice like ours does.

I want to be careful about the relationship itself, because this is where it would be easy to sell you something. Across psychotherapy generally, patients who report a stronger working relationship with their clinician do better, and that pattern holds in addiction treatment, though the association is weaker there than for most other conditions. It is also correlational, and it cannot be otherwise: no one can ethically assign patients to a good or a bad relationship, so the trial that would settle it will never be run. Patients who are improving may simply rate their doctors more warmly. I believe the relationship does real work, and I practice as though it does, but I am telling you that is a clinical conviction supported by association rather than a proven mechanism.

The same discipline applies to intensive long-term care management. It has been tested in a randomized trial. The population was severely affected: most had recently been homeless, and two-thirds were dependent on drugs as well as alcohol. Twelve months of coordinated integrated care did not improve abstinence over ordinary primary care. Our patients look nothing like that population, which is a reasonable argument that the result may not transfer. It is not a reason to pretend the trial does not exist.

So what is defensible: the structure works, the medications work, getting people into treatment at all is the biggest lever anyone has, and there are several routes to a good outcome rather than one. What we add is the judgment to pick the route and the continuity to adjust it.

Structure, monitoring, and accountability

In practice that means medical care, psychological treatment, a schedule with accountability in it, and attention to everything the drinking has been affecting.

It also increasingly means technology. Remote breath alcohol monitoring has become practical for everyday use, and wearable alcohol sensors are developing quickly. The framing determines whether these help. Monitoring imposed on a person is surveillance. Monitoring a person chooses is something else entirely, because it makes their commitment legible to themselves and to the people they asked to hold them to it. In our experience that second kind earns its place in the early months, when the internal signal is least reliable. I offer that as clinical experience rather than trial evidence.

Where treatment happens, and when it should not happen at home

Alcohol withdrawal can be medically dangerous and, in its severe forms, life threatening. Stopping abruptly after sustained heavy drinking can cause seizures or delirium. If you drink heavily every day, do not stop on your own. Get medical help to do it safely. Nothing in this article substitutes for being evaluated, and if you are in withdrawal and getting worse, call 911 or go to an emergency department.

With that said, here is how we think about setting. Outpatient treatment is our center of gravity, and for most of the people we treat it is possible when safety criteria are met. The randomized evidence behind that is real but narrow: a 1989 trial in 164 male veterans with mild to moderate withdrawal and no recent seizure or impending delirium found that outpatient management took less time than inpatient care, produced comparable functioning at six months, and caused no serious medical complications in either group. The honest counterweights are that more inpatients finished the process than outpatients, and that this was a narrow and highly specific study population, which limits how far the finding travels.

Selection is the whole ballgame. A history of withdrawal seizures or delirium tremens rules out home management on its own, because both are associated with a substantially higher chance of it happening again. Current withdrawal beyond mild severity rules it out too. Beyond those, we manage people in the hospital rather than at home when there is serious medical illness such as decompensated cirrhosis, advanced kidney disease, significant heart failure, oxygen-dependent lung disease, a seizure disorder, or recent head injury; when there is unstable psychiatric illness, active psychosis, or suicidal thinking; when someone cannot reliably monitor symptoms, take medication as directed, or get to follow-up and has no one to help; and in pregnancy, always. If someone starts at home and things move the wrong way, they come in.

Benzodiazepines sit in a category of their own. Standard guidance treats a co-occurring benzodiazepine problem as a reason to manage alcohol withdrawal in the hospital, and for most practices that is the right default. We handle some of these at home, because benzodiazepine dependence is something we treat routinely and the two problems often travel together. But doing so raises the bar rather than leaving it where it was: more supervision at home, tighter follow-up, someone reliable present, and an explicit plan in advance for when to go to the emergency department. That is a judgment we make case by case, not a general reassurance.

When someone needs a higher level of care, we can arrange it. I hold admitting privileges at a San Francisco hospital, and we coordinate with residential programs when the situation calls for one. The plan is always continuity back to outpatient care.

One more point matters, because it is where a lot of treatment fails. Medically supervised withdrawal is not treatment of alcohol use disorder. It manages a few dangerous days. Completing withdrawal and then receiving nothing further leaves the disorder itself untouched. That is why detox sold as a standalone product is close to a waste of everyone's time.

What this looks like in our practice

Full-scope medical practice matters more in this condition than in almost any other. Alcohol touches sleep, mood, blood pressure, the liver, cardiovascular risk, and nutrition. It often touches a prescription that needs rethinking. We can address all of it, coordinate with your therapist or psychiatrist, and adjust as the picture changes, rather than sending you to four places that do not talk to each other. If opioids or benzodiazepines are also part of your situation, we treat those too, and I have written separately about buprenorphine treatment and about tapering benzodiazepines.

Common questions

Am I drinking too much?

The standard thresholds are a starting point. The National Institute on Alcohol Abuse and Alcoholism defines heavy drinking as 4 or more drinks on any day or 8 or more per week for women, and 5 or more on any day or 15 or more per week for men, with a standard drink containing about 14 grams of alcohol. But thresholds describe populations, not people. The more useful questions are whether drinking is doing something for you that nothing else does, whether you have tried to cut back and found it harder than expected, and whether it is costing you sleep, mood, or relationships.

Can I learn to moderate instead of quitting?

Some people can, and the research on long-term recovery includes people who still drink sometimes. But severity is associated with lower odds of recovering while still drinking, and in our experience moderation attempted from inside active alcohol use disorder usually does not hold. Our approach is to sequence it: establish a period of abstinence, get real data about sleep, mood, and functioning, then decide together whether a structured moderation trial makes sense.

Do I have to go to rehab?

Usually not. Residential treatment is right for some people, and we will say so when it is. For most of the people we see, the combination of medical treatment, therapy, structure, and accountability works while they keep living their life.

What if naltrexone did not work for me?

Common, and not the end of the list. It is worth checking whether the attempt was adequate: the right dose, enough time, and actual treatment alongside it rather than the pill alone. If it genuinely did not help, there are further options, and we will be explicit about which have strong evidence and which are used off-label with thinner support.

Do you treat patients by telemedicine?

Not exclusively. Every patient establishes care in person at our San Francisco office. Once care is established, we can often use a hybrid approach and conduct some visits remotely when that is appropriate for the clinical situation.

How we approach this at My Doctor Medical Group

The question is not whether you are the kind of person who has to quit forever. It is what you are trying to protect, what the evidence says about getting you there, and what you are willing to try for the next six months. Those are answerable questions, and answering them is ordinary medical work rather than a verdict on your character.

We treat alcohol use disorder privately and without judgment, in a practice small enough that one physician knows your whole situation. If you are wondering whether any of this applies to you, contact us securely, or read more about our approach to alcohol use disorders.

This article is for general educational purposes only. It is not medical advice, it is not a substitute for evaluation by a physician who knows your situation, and reading it does not create a doctor and patient relationship. Please consult your own physician about your health. Nothing here should delay you from seeking care: if you are in withdrawal, feeling unwell, or in crisis, contact your physician, go to an emergency department, or call 911.

Sources

• Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study, a randomized controlled trial. JAMA, 2006;295(17):2003-2017. DOI: 10.1001/jama.295.17.2003
• Watkins KE, Ober AJ, Lamp K, et al. Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial. JAMA Internal Medicine, 2017;177(10):1480-1488. DOI: 10.1001/jamainternmed.2017.3947
• Saitz R, Cheng DM, Winter M, et al. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. JAMA, 2013;310(11):1156-1167. DOI: 10.1001/jama.2013.277609
• Flückiger C, Del Re AC, Wampold BE, Horvath AO. The alliance in adult psychotherapy: a meta-analytic synthesis. Psychotherapy, 2018;55(4):316-340. DOI: 10.1037/pst0000172
• Blodgett JC, Maisel NC, Fuh IL, et al. How effective is continuing care for substance use disorders? A meta-analytic review. Journal of Substance Abuse Treatment, 2014;46(2):87-97. DOI: 10.1016/j.jsat.2013.08.022
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA, 2014;311(18):1889-1900. DOI: 10.1001/jama.2014.3628
• McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA, 2023;330(17):1653-1665. DOI: 10.1001/jama.2023.19761 (see also the 2024 erratum, DOI: 10.1001/jama.2024.11331)
• Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One, 2014;9(2):e87366. DOI: 10.1371/journal.pone.0087366
• Agabio R, Saulle R, Rösner S, Minozzi S. Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews, 2023;1(1):CD012557. DOI: 10.1002/14651858.CD012557.pub3
• Chaignot C, Zureik M, Rey G, et al. Risk of hospitalisation and death related to baclofen for alcohol use disorders. Pharmacoepidemiology and Drug Safety, 2018;27(11):1239-1248. DOI: 10.1002/pds.4635
• Rigal L, Sidorkiewicz S, Tréluyer JM, et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction, 2020;115(7):1265-1276. DOI: 10.1111/add.14927
• Naudet F, Braillon A, Cristea IA, Lexchin J. Restoring the Bacloville trial: efficacy and harms. Addiction, 2020;115(11):2184-2186. DOI: 10.1111/add.15109
• Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Internal Medicine, 2020;180(5):728-736. DOI: 10.1001/jamainternmed.2020.0249
• Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcoholism: Clinical and Experimental Research, 2014;38(6):1481-1488. DOI: 10.1111/acer.12411
• Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 2022;7(19):e159863. DOI: 10.1172/jci.insight.159863
• Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry, 2025;82(4):395-405. DOI: 10.1001/jamapsychiatry.2024.4789
• Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet, 2026;407(10540):1687-1698. DOI: 10.1016/S0140-6736(26)00305-3
• Witkiewitz K, Wilson AD, Pearson MR, et al. Profiles of recovery from alcohol use disorder at three years following treatment. Addiction, 2019;114(1):69-80. DOI: 10.1111/add.14403
• Witkiewitz K, Pearson MR, Wilson AD, et al. Can alcohol use disorder recovery include some heavy drinking? A replication and extension up to 9 years following treatment. Alcoholism: Clinical and Experimental Research, 2020;44(9):1862-1874. DOI: 10.1111/acer.14413
• Dawson DA, Grant BF, Stinson FS, et al. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction, 2005;100(3):281-292. DOI: 10.1111/j.1360-0443.2004.00964.x
• Brower KJ. Assessment and treatment of insomnia in adult patients with alcohol use disorders. Alcohol, 2015;49(4):417-427. DOI: 10.1016/j.alcohol.2014.12.003
• Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry, 2016;3(8):760-773. DOI: 10.1016/S2215-0366(16)00104-8
• Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal of Drug Policy, 2010;21(3):202-207. DOI: 10.1016/j.drugpo.2009.10.010
• Volkow ND, Gordon JA, Koob GF. Choosing appropriate language to reduce the stigma around mental illness and substance use disorders. Neuropsychopharmacology, 2021;46(13):2230-2232. DOI: 10.1038/s41386-021-01069-4
• Goodson CM, Clark BJ, Douglas IS. Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcoholism: Clinical and Experimental Research, 2014;38(10):2664-2677. DOI: 10.1111/acer.12529
• Hayashida M, Alterman AI, McLellan AT, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. New England Journal of Medicine, 1989;320(6):358-365. DOI: 10.1056/NEJM198902093200605
• National Institute on Alcohol Abuse and Alcoholism. Understanding Alcohol Drinking Patterns. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-drinking-patterns